iSpecimen Raises $400,000 in Series D Preferred Stock Offering
iSpecimen raised $400,000 through a private placement of 500 Series D convertible preferred shares, with proceeds for working capital. The shares have an $8% annual dividend and conversion terms. The offering includes resale registration rights, E.F. Hutton's placement services, and a 90-day lock-up for insiders. According to the company, the financing is intended for general corporate purposes.
How this was made

The 30-second read
Why it matters
The $400k raise is a primary disclosure but small in scale, likely causing modest dilution and limited market reaction.
Market read
Primary micro‑cap capital raise with limited immediate price impact.
What to watch
Potential strategic partnership with E.F. Hutton and the convertible terms may become material if the company secures larger financing later.
Background
iSpecimen (ISPC) is a micro‑cap biotech that filed an 8‑K reporting a private placement of Series D convertible preferred shares.
Ticker impact
iSpecimen disclosed a $400,000 Series D convertible preferred stock private placement to fund working capital.
likely slight downward pressure as market prices in the new preferred shares
The raise is modest in size for a micro‑cap, but introduces convertible preferred shares that could dilute existing equity if converted.
Market effects
Minimal impact on the broader biotech/health‑tech sector.
Limited to U.S. micro‑cap investors.
Low
Counterpoint
The raise could be seen as a sign of confidence and may support a short‑term rally if the capital is deployed effectively.
Key entities
- companyiSpecimen Inc.
Issuer of the Series D preferred stock.
- financial_intermediaryE.F. Hutton
Placement agent for the private offering.